Cargando…
Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes
Chimeric antigen receptor (CAR) T cell therapy is now approved for the standard of care treatment of several types of relapsed or refractory hematologic malignancies. Future advances may extend cellular therapies to solid tumors or even non‐malignant diseases. As patient need grows, a clinical speci...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175904/ https://www.ncbi.nlm.nih.gov/pubmed/35844298 http://dx.doi.org/10.1002/jha2.357 |